Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHaleon Regulatory News (HLN)

Share Price Information for Haleon (HLN)

Share Price is delayed by 15 minutes
Get Live Data
321.20    0.30 (0.09%)
Bid:
320.40
Ask:
320.50
Spread: 0.10 (0.031%)
Market Cap: £28.42b
HLN Live PriceLast checked at - London Stock Exchange

Intraday Haleon Share Chart

Results of Haleon 2023 Annual General Meeting

20 Apr 2023 17:30

RNS Number : 9729W
Haleon PLC
20 April 2023
 

 

 

Haleon plc: Results of Haleon 2023 Annual General Meeting

 

20 April 2023: Haleon plc (the "Company") (LSE/NYSE: HLN) today announces that the following resolutions were decided by poll vote at the Company's 2023 Annual General Meeting ("AGM") which was held today.

 

Resolutions 20, 21, 22, 26, 27 and 28 were passed as special resolutions; all other resolutions were passed as ordinary resolutions. Full text of the resolutions is contained in the Company's Notice of AGM, which is available at www.haleon.com.

 

Haleon plc - Poll Results by All Shareholders

 

Resolution

Votes For

For (% of shares voted)

Votes Against

Against (% of shares voted)

Total Votes Cast (excluding withheld)

% of issued share capital voted1

Votes Withheld2

1

To receive the Annual Report and Accounts

7,888,244,555

99.97

2,091,612

0.03

7,890,336,167

85.44

15,542,626

2

To approve the Directors' Remuneration Report

7,769,899,285

98.72

101,062,356

1.28

7,870,961,641

85.23

34,883,051

3

To approve the Directors' Remuneration Policy

7,728,166,817

98.19

142,531,194

1.81

7,870,698,011

85.23

35,150,085

4

To declare a final dividend

7,881,354,609

99.84

12,563,481

0.16

7,893,918,090

85.48

11,958,174

5

To re-appoint Sir Dave Lewis

7,876,931,973

99.79

16,601,260

0.21

7,893,533,233

85.48

12,312,579

6

To re-appoint Brian McNamara

7,871,084,400

99.72

22,088,009

0.28

7,893,172,409

85.47

12,708,193

7

To re-appoint Tobias Hestler

7,866,797,285

99.67

26,254,733

0.33

7,893,052,018

85.47

12,786,833

8

To re-appoint Vindi Banga

7,867,335,102

99.67

26,175,768

0.33

7,893,510,870

85.48

12,336,941

9

To re-appoint Marie-Anne Aymerich

7,890,512,208

99.96

3,112,405

0.04

7,893,624,613

85.48

12,221,032

10

To re-appoint Tracy Clarke

7,865,519,126

99.64

28,102,790

0.36

7,893,621,916

85.48

12,223,729

11

To re-appoint Dame Vivienne Cox

7,867,915,608

99.67

25,707,980

0.33

7,893,623,588

85.48

12,222,787

12

To re-appoint Asmita Dubey

7,888,796,930

99.94

4,631,311

0.06

7,893,428,241

85.48

12,314,510

13

To re-appoint Deirdre Mahlan

7,855,947,958

99.52

37,606,999

0.48

7,893,554,957

85.48

12,290,655

14

To re-appoint David Denton

7,756,457,683

98.27

136,511,465

1.73

7,892,969,148

85.47

12,872,307

15

To re-appoint Bryan Supran

7,870,491,722

99.72

22,373,713

0.28

7,892,865,435

85.47

12,981,360

16

To appoint KPMG LLP as Auditor of the Company

7,887,876,048

99.92

6,610,659

0.08

7,894,486,707

85.49

11,357,094

17

To authorise the Audit & Risk Committee to set the Auditor's remuneration

7,875,138,402

99.77

18,463,151

0.23

7,893,601,553

85.48

12,247,103

18

To authorise the Company to make political donations

7,811,060,234

99.39

48,180,724

0.61

7,859,240,958

85.11

46,594,903

19

To authorise the Directors to allot shares

7,730,625,212

97.95

161,493,695

2.05

7,892,118,907

85.46

13,723,569

20

General authority to disapply pre-emption rights

 

7,808,260,233

99.20

63,131,891

0.80

7,871,392,124

85.24

34,452,867

21

Additional authority to disapply pre-emption rights

 

7,771,569,791

98.73

99,828,862

1.27

7,871,398,653

85.24

34,442,507

22

To shorten the notice period for General Meetings

7,681,982,554

97.55

192,963,273

2.45

7,874,945,827

85.28

30,905,583

23

Approve the Performance Share Plan 2023 Rules

7,797,546,898

98.82

93,471,605

1.18

7,891,018,503

85.45

14,811,682

24

Approve the Share Value Plan 2023 Rules

7,828,310,178

99.20

62,943,305

0.80

7,891,253,483

85.45

14,570,255

25

Approve the Deferred Annual Bonus Plan 2023 Rules

7,831,723,780

99.25

58,910,350

0.75

7,890,634,130

85.45

15,186,161

26

To authorise the Company to purchase its own shares

7,878,575,931

99.82

14,281,790

0.18

7,892,857,721

85.47

12,988,792

27

To authorise the Company to make off-market purchases of its own shares from Pfizer3

4,928,538,385

99.87

6,306,129

0.13

4,934,844,514

53.44

15,940,710

28

To authorise the Company to make off-market purchases of its own shares from the GSK Shareholders4

6,688,398,038

99.91

6,123,957

0.09

6,694,521,995

72.49

16,004,606

29

Approval of waiver of Rule 9 Offer obligation5

4,768,473,630

97.47

123,562,632

2.53

4,892,036,262

52.98

58,740,625

 

1 For the purposes of section 341 of the Companies Act 2006, Haleon plc's total issued share capital with voting rights as at 6.30pm on 18 April 2023, being the time at which a shareholder had to be registered in the Company's register of members in order to attend and vote at the AGM, was 9,234,573,831.

 

2 A "Vote withheld" is not a vote in law and is not counted in the calculation of the votes "For" or "Against" a resolution.

3 Pfizer has agreed not to vote any of the Ordinary shares held in respect of Resolution 27.

4 The GSK Shareholders, as defined on page 25 of the Notice of Meeting, have agreed not to vote any of the Ordinary shares held in respect of Resolution 28.

5 Pfizer and any person acting in concert with Pfizer are precluded from voting on Resolution 29.

 

 

 

 

 

 

Haleon plc - Poll Results by Independent Shareholders

 

Resolution

Votes For

For (% of shares voted)

Votes Against

Against (% of shares voted)

Total Votes Cast (excluding withheld)

% of issued share capital voted1

Votes Withheld2

8

To re-appoint Vindi Banga

4,912,225,248

99.47

26,175,768

0.53

4,938,401,016

78.64%

12,336,941

9

To re-appoint Marie-Anne Aymerich

4,935,402,354

99.94

3,112,405

0.06

4,938,514,759

78.65%

12,221,032

10

To re-appoint Tracy Clarke

4,910,409,272

99.43

28,102,790

0.57

4,938,512,062

78.65%

12,223,729

11

To re-appoint Dame Vivienne Cox

4,912,805,754

99.48

25,707,980

0.52

4,938,513,734

78.65%

12,222,787

12

To re-appoint Asmita Dubey

4,933,687,076

99.91

4,631,311

0.09

4,938,318,387

78.64%

12,314,510

13

To re-appoint Deirdre Mahlan

4,900,838,104

99.24

37,606,999

0.76

4,938,445,103

78.64%

12,290,655

 

1 Percentage of votes cast by independent shareholders for Resolutions 8, 9, 10, 11, 12 and 13 appointing Independent Non-Executive Directors exclude Pfizer's 2,955,113,626 shares.

2 A "Vote withheld" is not a vote in law and is not counted in the calculation of the votes "For" or "Against" a resolution.

As required by the Listing Rule 9.6.2R of the Financial Conduct Authority ("FCA"), copies of resolutions passed by the Company other than resolutions concerning ordinary business have been submitted to the FCA via the National Storage Mechanism and will shortly be available to the public for inspection at  https://data.fca.org.uk/#/nsm/nationalstoragemechanism.

 

 

Amanda Mellor 

Company Secretary 

 

 

About Haleon

Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.

 

For more information, please visit www.haleon.com.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
AGMQBLFLXZLLBBK
Date   Source Headline
1st Jun 20269:45 amRNSTotal Voting Rights and Capital
1st Jun 20267:00 amRNSTransactions in Own Shares
26th May 20267:00 amRNSTransactions in Own Shares
22nd May 202612:30 pmRNSDirector/PDMR Shareholding
18th May 20262:30 pmRNSDirector/PDMR Shareholding
18th May 20267:00 amRNSTransactions in Own Shares
11th May 20267:00 amRNSTransactions in Own Shares
7th May 20264:26 pmRNSEMTN programme publication of listing particulars
5th May 20267:00 amRNSTransactions in Own Shares
1st May 20263:30 pmRNSTotal Voting Rights and Capital
29th Apr 20264:48 pmRNSResults of Haleon 2026 Annual General Meeting
29th Apr 20267:00 amRNSHaleon 2026 Q1 Trading Statement
27th Apr 20267:00 amRNSTransactions in Own Shares
20th Apr 20267:00 amRNSTransactions in Own Shares
13th Apr 20267:00 amRNSTransactions in Own Shares
7th Apr 20267:00 amRNSTransactions in Own Shares
1st Apr 20269:00 amRNSTotal Voting Rights and Capital
30th Mar 20267:00 amRNSTransactions in Own Shares
24th Mar 20263:00 pmRNSDirector/PDMR Shareholding
23rd Mar 20267:00 amRNSTransactions in Own Shares
16th Mar 20267:00 amRNSTransactions in Own Shares
16th Mar 20267:00 amRNSTransactions in Own Shares
13th Mar 20262:30 pmRNSDirector/PDMR Shareholding
13th Mar 20262:00 pmRNSPublication of Annual Report 2025 & Notice of AGM
12th Mar 202610:00 amRNSCommencement of £500m Share Buyback Programme
2nd Mar 20269:30 amRNSTotal Voting Rights and Capital
25th Feb 20267:00 amRNSHaleon Preliminary 2025 Full Year Results
12th Feb 20269:00 amRNSDirector/PDMR Shareholding
2nd Feb 20263:30 pmRNSTotal Voting Rights and Capital
21st Jan 20262:45 pmRNSDirector Declaration
8th Jan 20261:30 pmRNSEvolution of operating model
6th Jan 20262:00 pmRNSDirector/PDMR Shareholding
2nd Jan 20267:00 amRNSTotal Voting Rights and Capital
2nd Jan 20267:00 amRNSTotal Voting Rights and Capital
15th Dec 202510:00 amRNSBoard and Committee Changes
10th Dec 20253:15 pmRNSDirector/PDMR Shareholding
1st Dec 202510:30 amRNSTotal Voting Rights and Capital
12th Nov 202511:00 amRNSDirector/PDMR Shareholding
10th Nov 20257:00 amRNSAppointment of Vindi Banga as Chair
3rd Nov 202511:30 amRNSTotal Voting Rights and Capital
30th Oct 20257:00 amRNSHaleon 2025 Q3 Trading Statement
10th Oct 202512:45 pmRNSDirector/PDMR Shareholding
2nd Oct 202510:05 amRNSDirector Declaration
2nd Oct 20257:00 amRNSTransaction in Own Shares & Buyback Update
1st Oct 202510:00 amRNSTotal Voting Rights and Capital
1st Oct 20257:00 amRNSTransaction in Own Shares
30th Sep 20257:00 amRNSTransaction in Own Shares
29th Sep 20257:00 amRNSTransaction in Own Shares
26th Sep 20251:30 pmRNSDirector/PDMR Shareholding
26th Sep 20257:00 amRNSTransaction in Own Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.